The partner you select for your early phase studies is critical in helping you achieve your overall development timeline efficiently and within budget. You need a CRO that has an established network of carefully selected sites centered around quality, medical safety and unparalleled expertise.
We understand the importance of selecting the right sites when executing Phase I studies, that is why each of our global facilities undergo a rigorous selection process including GCP audits and/or pre-selection assessment visits. We have executed master clinical service agreements or agreed to contract language with all our sites.
29 Early Development Sites Spanning Across 12 Countries
PPD’s global network of Phase I clinical sites offer access to a diverse pool of healthy volunteers and specialty populations across four continents. Many of our 29 strategically located facilities are located near hospitals and universities, allowing us access to hundreds of faculty members in fields such as pulmonology, anesthesiology and neurology. With over 100 studies awarded through our global network in the past five years, our areas of expertise include: renal impairment, hepatic impairment, Japanese Bridging, Chinese Bridging in China and NHV studies.
Overall Indications and Specialty Populations Through our Global Site Network
Overall Indications Include:
- Dermatological Conditions
- Infectious Diseases
- Sexual Disorders
Specialty Populations Include:
Ethnic Specialty Populations
Broad Early Development Experience
PPD’s three US based clinical research units are broadly experienced in special procedures with a dedicated focus on complex studies, first-in-human studies and neurodegenerative diseases. With over 30 years of experience in executing Phase I studies through our CRUs, our facilities are host to cutting-edge diagnostic tools, technology and registered medical experts.
- 180 beds
- Operational since 1986
- Large cohort and long-term confinement studies
- On-site pharmacy and labs
- 32 beds
- Adjacent to hospital
- Endocrinology and metabolic expertise
- Japanese Ethno-bridging studies
- 36 beds
- Neuroscience focused
- Alzheimer’s and neurodegenerative expertise
- Proximal to 125k community of 55+ individuals